Quick Summary — TAK scores higher on quality with 7.4/10 vs TLRY's 6.8/10. TAK trades at $15.18 while TLRY trades at $5.38. Both analyzed daily using SEC EDGAR data across 13 institutional models.
TAK scores higher with a 7.4/10 quality rating vs TLRY's 6.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $15.18, TAK trades +135.7% below its Bayesian DCF fair value of $35.78, while TLRY at $5.38 trades +71.5% above its estimate of $1.53. TAK shows a wider gap between price and intrinsic value.
TAK earns a Quality of Company score of 7.4/10 compared to TLRY's 6.8/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
TAK carries a LOW value trap risk (39/100) while TLRY shows WARN risk (45/100). Stocks with value trap scores above 40 may appear undervalued but face deteriorating fundamentals — declining margins, rising debt, or shrinking revenue can make the apparent discount a trap.
Both TAK and TLRY operate in Drug Manufacturers - Specialty & Generic, which has 79 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare TAK vs TLRY differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.